Updated: 3-ArriVent’s cancer drug failed to “significantly” delay disease progression, stock price plummeted
路透社2026/10/06 15:18Updated stock data and added analyst comments in paragraphs 8 and 10 Christy Santhosh - Reuters, October 6 - ArriVent BioPharma (AVBP.O) announced on Tuesday that its oral therapy for a rare form of lung cancer failed to significantly delay disease progression in a late-stage clinical trial, causing the company's share price to plunge by nearly 60% in early trading. The therapy, firmonertinib, was tested in treatment-naïve advanced non-small cell lung cancer (NSCLC) patients carrying a gene mutation known as EGFR exon 20 insertion, which may promote cancer growth. This mutation accounts for about 0.5% to 1% of all NSCLC cases. NSCLC makes up around 85% of all lung cancer cases. An assessment by independent reviewers showed that ArriVent’s 240 mg dose therapy extended median progression-free survival to 11 months in the trial, compared to just 9.5 months for the chemotherapy group. CEO Bing Yao stated that the improvement in progression-free survival (i.e., the period during which a patient's cancer does not worsen or spread) was not "significant". "These disappointing results are not what we had hoped for, especially for patients who... are in urgent need of more effective treatment options." The company said it is reviewing the complete dataset to determine the most appropriate development path for firmonertinib, and no new safety signals were observed in the trial. BTIG analyst Jeet Mukherjee noted that the main reason the trial appears to have failed was the control group's performance exceeding expectations—their progression-free survival reached 9.5 months, when only 7.5 to 8 months was anticipated; firmonertinib’s 11-month result matched the expected range of 9 to 11 months. Additionally, firmonertinib is currently undergoing an advanced clinical trial in NSCLC patients with rare EGFR PACC mutations in their tumors. "This result is a significant setback for the exon 20 mutation treatment space, but the PACC program still has clinical support," said Clear Street analyst Kaveri Pohlman. The therapy has been approved in China for NSCLC patients carrying specific mutations. (To aid non-English speakers, Reuters has automated the translation of its reports into several other languages. As automated translations may contain errors or lack necessary context, Reuters does not guarantee the accuracy of these translated texts and they are provided for reader convenience only. Reuters is not responsible for any damages or losses arising from the use of automated translation features.)
Stock price data updated, and analyst comments added in paragraphs 8 and 10
Christy Santhosh
Reuters, October 6 - ArriVent BioPharma (AVBP.O) said on Tuesday that its oral therapy for a rare form of lung cancer failed to significantly delay disease progression in a late-stage clinical trial, sending the company’s shares plunging nearly 60% in early trading.
The therapy, firmonertinib, was tested in patients with previously untreated advanced non-small cell lung cancer (NSCLC) who carry a gene variant called EGFR exon 20 insertion mutation, which may promote cancer growth.
This mutation accounts for about 0.5% to 1% of all non-small cell lung cancer (NSCLC) cases. NSCLC accounts for about 85% of all lung cancer cases.
An independent review found that in the trial, ArriVent’s 240 mg dose therapy extended the median progression-free survival to 11 months, compared with just 9.5 months for the chemotherapy group.
Chief Executive Officer Bing Yao said the improvement in progression-free survival – the time patients lived without the disease worsening or spreading – was not “significant.”
“These disappointing results are not what we had hoped for, especially for patients who... are in urgent need of more effective treatment options.”
The company said it is evaluating the full data set to determine the most appropriate development path for firmonertinib, and no new safety signals were observed in the trial.
BTIG analyst Jeet Mukherjee noted that the main reason the trial appears to have failed is that the control group outperformed expectations—the progression-free survival reached 9.5 months versus the expected 7.5 to 8 months, while the 11 months seen with firmonertinib was in line with the expected range of 9 to 11 months.
In addition, firmonertinib is currently being tested in a late-stage clinical trial in NSCLC patients with rare EGFR PACC mutations in their tumors.
“This is a major setback for the exon 20 mutation treatment field, but the PACC program still has clinical support,” said Clear Street analyst Kaveri Pullman.
The therapy has been approved in China for NSCLC patients carrying certain mutations.
(To make its reporting more accessible to non-native English speakers, Reuters automatically translates its articles into several other languages. Automatic translation may contain errors or omit context, so Reuters does not guarantee the accuracy of such translations, which are provided for reader convenience only. Reuters accepts no responsibility for any damage or loss resulting from the use of automatic translation.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ-Australia's Kelsian shares rise as asset sale triggers Morningstar's cautious optimism
Latest developments on October 7th – Kelsian Group (KLS.AX) shares briefly rose 1% to A$3.93 before narrowing gains to 0.3% by midday in Sydney. Morningstar holds a positive view on the transport operator’s recently announced A$150 million (US$104.76 million) sale of travel assets in mid-September. The investment research firm noted that this divestment relieves the transportation and travel operator from reliance on discretionary-spending businesses such as resorts, cruises, and tours. It also stated that the sale enables management to focus more on core operations and moderately reduces capital intensity. However, Morningstar pointed out that the sale means profits from the marine segment will still be "discretionary in nature." It added that the sale will leave the company’s earnings mainly dependent on its US interstate coach business, which is characterized by short-term contracts without cost-adjustment mechanisms and serves highly volatile sectors such as technology, oil, and gas. Year to date, the share price is down 8.2%. (US$1 = A$1.4318) (For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Automated translation may be inaccurate or may not completely reflect the required context; Reuters does not guarantee the accuracy of translated texts, which are provided solely for reader convenience. Reuters is not responsible for any harm or loss arising from the use of automatic translation.)
JPMorgan raises Gilead Sciences' target price to $170.
BUZZ - Australian winemaker Treasury Wine recovers early losses, Jefferies believes its troubles in the US are easing
October 7th - Treasury Wine Estates (TWE.AX) shares recovered a 1.8% loss in afternoon trading and were basically flat. Jefferies maintained a "Hold" rating on TWE and an AUD 6 target price, stating that although excess inventory and rising costs in the US market are limiting upside potential, TWE’s underperformance relative to the broader market has been narrowing. The brokerage expects a 1.2% increase in EBIT for fiscal year 2027 and notes that the US wine market is showing moderate growth in the higher price segment. Jefferies mentioned that the price segment below $20 still faces significant challenges and emphasized that low-priced wines continue to face pressure. The brokerage pointed out that competitor Constellation Brands’ (STZ.N) wine and spirits business saw organic sales increase by 17.2% in the second quarter, with sales to retailers up by 10.2%. TWE shares have risen 6.1% year-to-date. (For the convenience of non-English speakers, Reuters offers automated translations of its report into a number of other languages. Automated translation may contain errors or may not capture the intended context, and Reuters does not guarantee the accuracy of this text. It is provided only for convenience, and Reuters is not liable for any damage or loss caused by the use of automated translation.)
Bitcoin price falls below 84,000 dollars, oil prices and the US dollar rise
Crypto prices
More
